[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558827":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":28,"locations":24,"responsibleParty":34,"collaborators":36,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":24,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":24,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":24,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":24},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Operation group","EXPERIMENTAL","Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy",[13],"Procedure: Transnasal transsphenoidal pituitary lesion resection under neuroendoscopy",{"label":15,"type":16,"description":17,"interventionNames":18},"Drug group","ACTIVE_COMPARATOR","Bromocriptin 2.5mg, 2-3 times a day",[19],"Drug: Bromocriptin 2.5mg, 2-3 times a day",[21,25],{"type":22,"name":11,"description":11,"armGroupLabels":23,"otherNames":24},"PROCEDURE",[9],null,{"type":26,"name":17,"description":17,"armGroupLabels":27,"otherNames":24},"DRUG",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Qun Wu, Doctor","CONTACT","+86-13605810393","2192010@zju.edu.cn",{"type":35,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[37,39,41,43],{"name":38,"class":6},"Peking Union Medical College Hospital",{"name":40,"class":6},"West China Hospital",{"name":42,"class":6},"First Affiliated Hospital of Wenzhou Medical University",{"name":44,"class":45},"Ningbo Medical Center Lihuili Hospital","OTHER_GOV","100558827","surgical-and-pharmacological-efficacy-of-knosp-grade-0-2-prolactinoma-100558827",false,"NCT06556186","Surgical and Pharmacological Efficacy of Knosp Grade 0-2 Prolactinoma","Inclusion Criteria:\n\n* Prolactin level greater than three times the normal upper limit\n* MRI indicates Knosp Grade 0-2 pituitary adenoma\n\nExclusion Criteria:\n\n* MRI indicates Knosp grade 3-4 pituitary adenoma\n* Taking antidepressants or other psychotropic drugs\n* Patients allergic to bromocriptine or cannot tolerate surgery\n* Women defined as surgical infertility (i.e. hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or amenorrhea for more than 2 years\n* Critical illness patients, such as those with progressive consciousness disorders, cerebral hernias, and other emergency situations","ALL","20 Years","40 Years",{"count":56,"type":57},600,"ESTIMATED","INTERVENTIONAL",[60],"NA","The investigators carried out a multi-center comparative study, involving hospitals including the Second Affiliated Hospital of Zhejiang University School of Medicine, Peking Union Medical College Hospital, West China Hospital, Wenzhou First Hospital, and Li Huili Hospital. This study aimed to compare the efficacy of medication and surgery for specific subtypes of microadenomas and clearly defined macroadenomas (Knosp grades 0-2), in order to determine which is more effective and which has fewer benefits, thereby enhancing the evidence base.",[63],"Pituitary Tumor",[65],"pituitary tumor","NOT_YET_RECRUITING","2024-08-13",{"date":69,"type":70},"2024-08-15","ACTUAL",{"date":72,"type":57},"2024-10-01",{"date":74,"type":57},"2027-03-31",{"name":5,"class":6}]